Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XBiotech Inc (NASDAQ: XBIT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. XBiotech is a British Columbia, Canada corporation with headquarters in Austin, Texas, and it uses its SEC reports to communicate material information about governance, executive compensation, shareholder votes and other corporate matters related to its True Human™ antibody business.
Through current reports on Form 8‑K, XBiotech has disclosed events such as the appointment of new members to its board of directors and their roles on the Audit and Compensation Committees, as well as the terms of an executive employment agreement that outlines compensation and severance arrangements for a senior leader. Other 8‑K filings describe material agreements and provide context on how the company structures leadership transitions and board oversight.
The company’s definitive proxy statement on Schedule 14A details items presented at its annual meeting of shareholders, including the election of directors, ratification of its independent registered public accounting firm, advisory votes on executive compensation and approval of an equity incentive plan. The proxy materials also explain voting procedures, record dates and how shareholders can participate in the virtual annual meeting format.
On Stock Titan, these filings are available alongside AI‑powered summaries that highlight key points from lengthy documents such as proxy statements and 8‑K exhibits. Users can review vote results, committee composition, and compensation structures, and can track how XBiotech’s governance and corporate policies evolve over time. Real‑time updates from EDGAR, combined with AI explanations, help readers quickly understand the implications of new filings without having to parse every page of the underlying documents.
XBiotech Inc. shareholder W. Thorpe McKenzie filed an amended Schedule 13G reporting beneficial ownership of 3,006,259 common shares, representing 9.76% of XBiotech’s outstanding common shares as of December 31, 2025. This figure includes 302,500 shares issuable upon exercise of stock options that are exercisable within 60 days of that date.
McKenzie has sole voting and dispositive power over 2,899,971 shares and shared voting and dispositive power over 106,288 shares, which are held by related parties including the McKenzie Foundation, his spouse, and a trust for his stepchildren. He disclaims beneficial ownership of those related-party shares except to the extent of his pecuniary interest. The ownership percentage is based on 30,487,731 shares outstanding as of December 31, 2025 plus the option shares.
XBiotech Inc. insider ownership disclosure: Chairman of the Board John Simard reports beneficial ownership of 5,719,775 common shares of XBiotech Inc. as of December 31, 2025, representing 17.7% of the company’s common shares. This includes 3,823,166 shares held directly and 1,896,609 additional shares issuable upon exercise of stock options that are immediately exercisable within 60 days of December 31, 2025.
The 17.7% figure is based on 30,487,731 XBiotech common shares outstanding as of December 31, 2025, plus the 1,896,609 option shares attributed to Simard. He reports sole voting and dispositive power over all 5,719,775 shares, with no shared voting or dispositive authority and no group arrangements disclosed.
XBiotech Inc. reported Q3 2025 results, posting a net loss of $6.0 million as operating expenses fell with no active clinical trials. Cash and cash equivalents were $147.4 million at September 30, 2025, supporting ongoing R&D and facility plans.
Research and development expense was $5.1 million in Q3 (down from $7.1 million), mainly from lower clinical and manufacturing activity. General and administrative expense was $1.0 million. Other income reflected $1.4 million of interest income and a $1.2 million foreign exchange loss. For the nine months, net loss was $18.6 million.
The company repaid in full a $10 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. On October 2, 2025, XBiotech entered a new executive employment agreement with its CEO, providing a $1,250,000 base salary, eligibility for a $4,530,442 base bonus, and severance equal to three years of base salary and base bonus upon certain separations. Shares outstanding were 30,487,731 as of November 12, 2025.
XBiotech Inc. (XBIT) reported a Form 4 for director Craig Rademaker. On October 1, 2025, he received a nonstatutory stock option grant for 92,104 options with an exercise price of $2.64 per share under the company’s 2025 Equity Incentive Plan. The options relate to common stock and were acquired at no cost.
The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year term expiring on October 1, 2035. Following the transaction, 92,104 derivative securities are beneficially owned directly.
XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.
XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.
XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.
The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.
XBiotech Inc., a British Columbia, Canada corporation listed on the NASDAQ Global Select Market under the symbol XBIT, submitted an amended current report to clarify previously described background information for one of its directors. The update concerns how Craig Rademaker’s role with private equity firms is characterized.
The company now states that Mr. Rademaker is a consultant to a number of Canadian private equity firms and that his responsibilities principally include capital markets activities. No changes to his directorship, compensation, or company financials are discussed in this update.
XBiotech Inc. has entered into a new Executive Employment Agreement with its CEO and President, John Simard, effective October 1, 2025, replacing all prior arrangements. The agreement, approved by the Compensation Committee of independent directors, formalizes his pay structure and is intended to recognize his past and ongoing contributions and support leadership continuity and any future transition.
Under the agreement, Mr. Simard’s annual base salary remains at USD $1,250,000, and he is eligible for an annual base bonus of USD $4,530,442.00, reflecting his average bonus over the past five years, with actual amounts set each year by the committee and both salary and bonus adjusted annually for inflation. On retirement, disability, or termination without cause, he or his estate is entitled to a cash severance equal to three full calendar years of base salary and three full calendar years of base bonus, paid after execution of a release, and on retirement he will also serve as a consultant for at least 18 months while continuing to receive base salary. Severance is reduced in the event of termination for cause as described in the agreement.
Initial Form 3 filed for XBiotech Inc. (XBIT) by David Soffer, who identifies his relationship to the issuer as a director. The filing states that the reporting person does not beneficially own any securities of the issuer. The Form 3 is an initial Section 16 filing that discloses current ownership; in this case there are no non-derivative or derivative holdings reported.